sphingotest® bio-ADM · High level of bio-ADM at admission identifies patients who will benefit...
6
sphingotest® bio-ADM A Marker for Acute Heart Failure Diagnosis of Incomplete Decongeson and Guidance of Diurec Therapy sphingotest® biomarker assays
Transcript of sphingotest® bio-ADM · High level of bio-ADM at admission identifies patients who will benefit...
sphingotest® bio-ADMA Marker for Acute Heart Failure Diagnosis of Incomplete Decongestion and Guidance of Diuretic Therapy
sphingotest® bio-ADM: A marker for incomplete decongestion
sphingotest® acute biomarkers
Reliable• Worldwidevalidatedinten-thousandsofpatients• Simpleandrobustcut-off• Independentofcomorbiditiesandinflammation
Practical• Bloode.g.plasmaassamplematrix• Stableatroomtemperature• 1hourtoresult
Valuable • Reflectsseverityofcongestion• Enablesclosemonitoringofdiuretictherapy• Supportsdischargedecisionbyrecognition ofcompletedecongestion
Forfurtherinformationpleasecontact:
+49 3302 20565-0 | [email protected]
sphingotec GmbHNeuendorfstrasse15A|16761Hennigsdorf|Germany|www.sphingotec.com
sphi
ngot
est®
bio
mar
ker a
ssay
s
Early prediction for early intervention
Close monitoring for discharge decision
Unaffected by comorbidities and inflammation
Simple and robust cut-off
Easy handling of blood samples
sphingotest® bio-ADMPrediction, Diagnosis and Monitoring of Acute Circulatory Failure e.g. in Sepsis and Incomplete Decongestion in Acute Heart Failure
sphingotest® penKid Prediction, Diagnosis and Monitoring of Acute Kidney Injury
bio-ADM reflects the status of congestion in acute heart failuresphingotest®bio-ADMistheonlyimmunoassaytomeasuretheplasmalevelofthebiologicalactiveAdrenomedullin,avasoactivehormonethatregulatesbloodpressureandvascularintegrity.
Serialmeasurementofbio-ADMsupportsclosemonitoringofdiuretictherapyinacuteheartfailureandenablesearlydiagnosisofincompletedecongestion.
Simple validated cut-off
Mostpatientswithacuteheartfailure(AHF)sufferfromsymptomsofcongestion.
Highlevelofbio-ADMatadmissionidentifiespatientswhowillbenefitfromadecongestiontherapye.g.bydiuretictreatment..
bio-ADMlevelcorrelateswiththeseverityofcongestion.Therebybio-ADMsupportsdecisionsondiuretictherapytoachievetheprimarygoalofcompletedecongestion.
To assess congestion status and monitor diuretic therapy
To ensure complete decongestion and improve hospital outcomesIncompletedecongestionisthemajorreasonforrehospitalizationandpost-dischargemortalityinAHFpatients.
Diuretictherapyshouldbecontinuedforpatientswithhighbio-ADMplasmalevels>70pg/mL.
Decreasingbio-ADMlevelsshowifapatientisrespondingtothediuretictherapy.
Adecreaseinbio-ADMconcentrationbelowthecut-offindicatescompletedecongestion.
70 pg/mL
bio-ADM ➔
time
AHF patient requires diuretics
low risk of rehospitalizationand mortality
Congestion
bio-ADM concentration 70 pg/mL
Completedecongestion
bio-AD
Mcon
centratio
n
Successfultreatment
Complete decongestion
bio-ADM in normal range
high risk of rehospitalizationand mortality
Admission Monitoring of diuretic therapy
Discharge
bio-ADM reflects the status of congestion in acute heart failuresphingotest®bio-ADMistheonlyimmunoassaytomeasuretheplasmalevelofthebiologicalactiveAdrenomedullin,avasoactivehormonethatregulatesbloodpressureandvascularintegrity.
Serialmeasurementofbio-ADMsupportsclosemonitoringofdiuretictherapyinacuteheartfailureandenablesearlydiagnosisofincompletedecongestion.
Simple validated cut-off
Mostpatientswithacuteheartfailure(AHF)sufferfromsymptomsofcongestion.
Highlevelofbio-ADMatadmissionidentifiespatientswhowillbenefitfromadecongestiontherapye.g.bydiuretictreatment..
bio-ADMlevelcorrelateswiththeseverityofcongestion.Therebybio-ADMsupportsdecisionsondiuretictherapytoachievetheprimarygoalofcompletedecongestion.
To assess congestion status and monitor diuretic therapy
To ensure complete decongestion and improve hospital outcomesIncompletedecongestionisthemajorreasonforrehospitalizationandpost-dischargemortalityinAHFpatients.
Diuretictherapyshouldbecontinuedforpatientswithhighbio-ADMplasmalevels>70pg/mL.
Decreasingbio-ADMlevelsshowifapatientisrespondingtothediuretictherapy.
Adecreaseinbio-ADMconcentrationbelowthecut-offindicatescompletedecongestion.
70 pg/mL
bio-ADM ➔
time
AHF patient requires diuretics
low risk of rehospitalizationand mortality
Congestion
bio-ADM concentration 70 pg/mL
Completedecongestion
bio-AD
Mcon
centratio
n
Successfultreatment
Complete decongestion
bio-ADM in normal range
high risk of rehospitalizationand mortality
Admission Monitoring of diuretic therapy
Discharge
bio-ADM reflects the status of congestion in acute heart failuresphingotest®bio-ADMistheonlyimmunoassaytomeasuretheplasmalevelofthebiologicalactiveAdrenomedullin,avasoactivehormonethatregulatesbloodpressureandvascularintegrity.
Serialmeasurementofbio-ADMsupportsclosemonitoringofdiuretictherapyinacuteheartfailureandenablesearlydiagnosisofincompletedecongestion.
Simple validated cut-off
Mostpatientswithacuteheartfailure(AHF)sufferfromsymptomsofcongestion.
Highlevelofbio-ADMatadmissionidentifiespatientswhowillbenefitfromadecongestiontherapye.g.bydiuretictreatment..
bio-ADMlevelcorrelateswiththeseverityofcongestion.Therebybio-ADMsupportsdecisionsondiuretictherapytoachievetheprimarygoalofcompletedecongestion.
To assess congestion status and monitor diuretic therapy
To ensure complete decongestion and improve hospital outcomesIncompletedecongestionisthemajorreasonforrehospitalizationandpost-dischargemortalityinAHFpatients.
Diuretictherapyshouldbecontinuedforpatientswithhighbio-ADMplasmalevels>70pg/mL.
Decreasingbio-ADMlevelsshowifapatientisrespondingtothediuretictherapy.
Adecreaseinbio-ADMconcentrationbelowthecut-offindicatescompletedecongestion.
70 pg/mL
bio-ADM ➔
time
AHF patient requires diuretics
low risk of rehospitalizationand mortality
Congestion
bio-ADM concentration 70 pg/mL
Completedecongestion
bio-AD
Mcon
centratio
n
Successfultreatment
Complete decongestion
bio-ADM in normal range
high risk of rehospitalizationand mortality
Admission Monitoring of diuretic therapy
Discharge
bio-ADM reflects the status of congestion in acute heart failuresphingotest®bio-ADMistheonlyimmunoassaytomeasuretheplasmalevelofthebiologicalactiveAdrenomedullin,avasoactivehormonethatregulatesbloodpressureandvascularintegrity.
Serialmeasurementofbio-ADMsupportsclosemonitoringofdiuretictherapyinacuteheartfailureandenablesearlydiagnosisofincompletedecongestion.
Simple validated cut-off
Mostpatientswithacuteheartfailure(AHF)sufferfromsymptomsofcongestion.
Highlevelofbio-ADMatadmissionidentifiespatientswhowillbenefitfromadecongestiontherapye.g.bydiuretictreatment..
bio-ADMlevelcorrelateswiththeseverityofcongestion.Therebybio-ADMsupportsdecisionsondiuretictherapytoachievetheprimarygoalofcompletedecongestion.
To assess congestion status and monitor diuretic therapy
To ensure complete decongestion and improve hospital outcomesIncompletedecongestionisthemajorreasonforrehospitalizationandpost-dischargemortalityinAHFpatients.
Diuretictherapyshouldbecontinuedforpatientswithhighbio-ADMplasmalevels>70pg/mL.
Decreasingbio-ADMlevelsshowifapatientisrespondingtothediuretictherapy.
Adecreaseinbio-ADMconcentrationbelowthecut-offindicatescompletedecongestion.
70 pg/mL
bio-ADM ➔
time
AHF patient requires diuretics
low risk of rehospitalizationand mortality
Congestion
bio-ADM concentration 70 pg/mL
Completedecongestion
bio-AD
Mcon
centratio
n
Successfultreatment
Complete decongestion
bio-ADM in normal range
high risk of rehospitalizationand mortality
Admission Monitoring of diuretic therapy
Discharge
sphingotest® bio-ADMA Marker for Acute Heart Failure Diagnosis of Incomplete Decongestion and Guidance of Diuretic Therapy
sphingotest® bio-ADM: A marker for incomplete decongestion
sphingotest® acute biomarkers
Reliable• Worldwidevalidatedinten-thousandsofpatients• Simpleandrobustcut-off• Independentofcomorbiditiesandinflammation
Practical• Bloode.g.plasmaassamplematrix• Stableatroomtemperature• 1hourtoresult
Valuable • Reflectsseverityofcongestion• Enablesclosemonitoringofdiuretictherapy• Supportsdischargedecisionbyrecognition ofcompletedecongestion
Forfurtherinformationpleasecontact:
+49 3302 20565-0 | [email protected]
sphingotec GmbHNeuendorfstrasse15A|16761Hennigsdorf|Germany|www.sphingotec.com
sphi
ngot
est®
bio
mar
ker a
ssay
s
Early prediction for early intervention
Close monitoring for discharge decision
Unaffected by comorbidities and inflammation
Simple and robust cut-off
Easy handling of blood samples
sphingotest® bio-ADMPrediction, Diagnosis and Monitoring of Acute Circulatory Failure e.g. in Sepsis and Incomplete Decongestion in Acute Heart Failure
sphingotest® penKid Prediction, Diagnosis and Monitoring of Acute Kidney Injury
sphingotest® bio-ADMA Marker for Acute Heart Failure Diagnosis of Incomplete Decongestion and Guidance of Diuretic Therapy
sphingotest® bio-ADM: A marker for incomplete decongestion
sphingotest® acute biomarkers
Reliable• Worldwidevalidatedinten-thousandsofpatients• Simpleandrobustcut-off• Independentofcomorbiditiesandinflammation
Practical• Bloode.g.plasmaassamplematrix• Stableatroomtemperature• 1hourtoresult
Valuable • Reflectsseverityofcongestion• Enablesclosemonitoringofdiuretictherapy• Supportsdischargedecisionbyrecognition ofcompletedecongestion
Forfurtherinformationpleasecontact:
+49 3302 20565-0 | [email protected]
sphingotec GmbHNeuendorfstrasse15A|16761Hennigsdorf|Germany|www.sphingotec.com
sphi
ngot
est®
bio
mar
ker a
ssay
s
Early prediction for early intervention
Close monitoring for discharge decision
Unaffected by comorbidities and inflammation
Simple and robust cut-off
Easy handling of blood samples
sphingotest® bio-ADMPrediction, Diagnosis and Monitoring of Acute Circulatory Failure e.g. in Sepsis and Incomplete Decongestion in Acute Heart Failure
sphingotest® penKid Prediction, Diagnosis and Monitoring of Acute Kidney Injury
